Literature DB >> 20437401

Inflammation in the pathophysiology of essential hypertension.

Fabrizio Montecucco1, Aldo Pende, Alessandra Quercioli, François Mach.   

Abstract

In spite of the huge amount of research recently performed in this area, the pathogenesis of human hypertension remains elusive. Thus, hypertension has to be defined as "essential" for the majority of patients with high blood pressure. Given the lack of animal models useful to investigate essential hypertension, we analyze and discuss both clinical and basic research studies indicating that essential hypertension should be considered as a potential multifactorial inflammatory disease. The pathophysiology of essential hypertension might result from interactions between genetic and environmental factors. Morphological abnormalities in the renal parenchyma and arteries have also been shown to determine hypertension. Inflammatory processes might induce renal vasoconstriction, ischemia and injury that can sustain systemic hypertension. Arterial and tubulointerstitial infiltration of inflammatory cells in response to renal damage might further increase renal and vascular alterations through the production of oxidants and other soluble inflammatory mediators. The present review gives an update regarding the latest research on the possible direct role of inflammation in the pathophysiology of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20437401     DOI: 10.5301/jn.2010.4729

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  23 in total

Review 1.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 2.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 3.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

4.  Role of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension.

Authors:  Youping Wang; Mingjun Zhu; Hui Xu; Lin Cui; Weihong Liu; Xiaoxiao Wang; Si Shen; Donna H Wang
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-13

Review 5.  Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?

Authors:  Saeed R Khan
Journal:  Urol Res       Date:  2012-01-04

6.  Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension.

Authors:  Sevtap Han; Mecit Orhan Uludag; Suzan Emel Usanmaz; Fatma Ayaloglu-Butun; Kamil Can Akcali; Emine Demirel-Yilmaz
Journal:  Mol Biol Rep       Date:  2014-09-19       Impact factor: 2.316

7.  Sex and age differences in the relation of depressive symptoms with blood pressure.

Authors:  Mauli T Shah; Alan B Zonderman; Shari R Waldstein
Journal:  Am J Hypertens       Date:  2013-08-19       Impact factor: 2.689

8.  Protective effect of olmesartan against cardiac ischemia/reperfusion injury in spontaneously hypertensive rats.

Authors:  Xin Lu; Yan-Wen Bi; Ke-Biao Chen; Hong-Yue Wang
Journal:  Exp Ther Med       Date:  2015-03-20       Impact factor: 2.447

9.  Urinary F2-isoprostanes and the risk of hypertension.

Authors:  Charles David Melton; Ruiyan Luo; Brett J Wong; Ivan Spasojevic; Lynne E Wagenknecht; Ralph B D'Agostino; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2017-05-17       Impact factor: 3.797

Review 10.  Nephrolithiasis and hypertension: possible links and clinical implications.

Authors:  Adamasco Cupisti; Claudia D'Alessandro; Sara Samoni; Mario Meola; Maria Francesca Egidi
Journal:  J Nephrol       Date:  2014-02-28       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.